Medicinova inc (MNOV)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

-

0

0

0

-

-

-

-

0

0

Operating expenses:
Research, development and patents

5,695

6,079

4,464

5,683

5,597

5,625

6,568

5,467

4,984

4,223

3,657

3,279

3,344

3,519

3,841

3,538

3,372

3,017

2,886

3,192

3,231

3,259

3,414

3,307

3,417

3,365

3,205

3,292

3,830

5,013

5,675

6,483

7,039

7,784

8,521

9,145

0

0

0

Cost of revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

General and administrative

6,280

7,952

7,834

10,997

10,301

9,961

11,932

9,798

9,685

8,803

7,402

6,834

7,169

7,362

8,335

7,388

6,626

5,805

5,582

6,027

5,842

5,963

5,997

6,002

6,549

6,657

6,700

6,817

6,273

6,734

7,119

7,772

8,157

8,323

8,233

7,853

0

0

0

Total operating expenses

11,976

14,031

12,299

16,681

15,899

15,586

18,501

15,265

14,670

13,027

11,060

10,114

10,513

10,881

12,177

10,926

9,999

8,822

8,469

9,220

9,074

9,223

9,412

9,309

9,966

10,023

9,906

10,110

10,104

11,747

12,795

14,256

15,196

16,108

16,754

16,998

0

0

0

Operating loss

-11,976

-14,031

-12,299

-16,681

-15,899

-15,586

-18,501

-15,265

-14,670

-13,027

-11,060

-10,114

-10,513

-10,881

-12,177

-10,926

-9,999

-8,822

-8,469

-9,220

-9,074

-9,223

-3,412

-3,309

-3,966

-4,020

-9,869

-9,989

-9,489

-10,945

-12,026

-13,571

-15,005

-16,108

-16,754

-16,998

0

0

0

Interest income

1,067

1,148

1,190

1,170

1,112

939

713

487

261

145

102

73

67

66

61

59

47

39

27

26

30

36

39

37

32

20

17

13

15

24

34

38

47

62

83

276

0

0

0

Other income (expense)

-36

-46

-51

-50

-37

-22

-43

-25

-37

-25

-69

-63

-45

-47

30

50

53

54

43

21

0

-

0

0

-

24

16

30

29

29

20

2

33

81

132

180

0

0

0

Debt related credit/(charge)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Write-off of debt related costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Impairment charge on investment securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

Foreign exchange gain/(loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

1,595

2,254

2,661

0

0

0

Loss before income taxes

-

-

-

-

-

-

-

-

-

-12,907

-11,001

-10,082

-10,494

-10,862

-12,146

-10,918

-10,005

-8,837

-8,493

-9,225

-9,060

-9,199

-3,394

-3,291

-3,955

-4,024

-9,868

-10,006

-9,503

-10,950

-12,013

-13,533

-15,933

-17,722

0

0

0

-

-

Income tax (expense)

-

-

-

-

-

-

-

-

-

-1,744

7

7

6

3

5

5

5

7

-2

-2

-2

-3

6

6

6

4

8

0

0

-

0

-

-

-

-

0

-

0

0

Net loss applicable to common stockholders

-10,958

-12,941

-11,165

-15,566

-14,829

-14,675

-16,070

-13,045

-12,689

-11,163

-11,009

-10,090

-10,500

-10,865

-12,152

-10,924

-10,011

-8,845

-8,450

0

0

-

0

-

-

-

-

-

-

-

-12,030

-13,545

-15,945

-17,734

-19,931

-20,371

0

0

0

Accretion to redemption value of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

Deemed dividend resulting from beneficial conversion feature on Series C redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

Net loss applicable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,297

-3,961

-4,028

-9,875

-10,017

-9,513

-10,961

-12,030

-13,545

-15,945

-17,734

-19,931

-20,371

0

0

0

Basic and diluted net loss per common share

-0.06

-0.05

-0.05

-0.09

-0.11

0.00

-0.16

-0.08

-0.12

-0.04

-0.11

-0.08

-0.09

-0.04

-0.08

-0.10

-0.11

-0.09

-0.06

-0.09

-0.09

-0.09

-0.10

-0.09

-0.10

0.19

-0.10

-0.14

-0.14

-0.14

-0.14

-0.14

-0.24

-0.19

-0.25

-0.31

-0.45

-0.46

-0.35

Shares used to compute basic and diluted net loss per common share

43,949

43,755

43,343

43,069

42,467

41,930

41,879

41,557

39,132

36,218

35,156

34,646

34,527

34,537

34,476

32,576

30,356

30,017

26,931

24,827

24,538

24,282

24,149

24,141

23,697

22,497

22,301

20,299

17,691

17,275

16,585

16,143

16,088

16,058

15,327

15,319

12,547

12,453

12,431

Net loss applicable to common stockholders

-10,958

-12,941

-11,165

-15,566

-14,829

-14,675

-16,070

-13,045

-12,689

-11,163

-11,009

-10,090

-10,500

-10,865

-12,152

-10,924

-10,011

-8,845

-8,450

0

0

-

0

-

-

-

-

-

-

-

-12,030

-13,545

-15,945

-17,734

-19,931

-20,371

0

0

0

Net loss applicable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,297

-3,961

-4,028

-9,875

-10,017

-9,513

-10,961

-12,030

-13,545

-15,945

-17,734

-19,931

-20,371

0

0

0

Other comprehensive loss, net of tax:
Foreign currency translation adjustments

2

0

1

1

-6

1

0

1

5

1

-9

-7

-1

6

16

15

8

-1

-17

-25

-23

-20

-6

1

-3

-12

-18

-16

-11

-11

-3

-0

-0

-1

0

0

0

-

-

Comprehensive loss

-10,955

-12,941

-11,164

-15,565

-14,835

-14,673

-16,069

-13,043

-12,684

-11,161

-11,018

-10,097

-10,502

-10,859

-12,135

-10,908

-10,003

-8,846

-8,507

-9,248

-9,081

-9,215

-3,407

-3,296

-3,965

-4,041

-9,894

-10,034

-9,524

-10,972

-12,033

-13,546

-15,945

-17,735

0

0

0

-

-